From access to uptake: Reflections from EMIG’s quarterly meeting
CF presented at the Ethical Medicines Industry Group quarterly [...]
Dementia Action Week: what acting on dementia actually requires
One in three people with dementia in the UK [...]
Sandboxes done right: Why healthcare innovation stalls before it reaches patients
In 2017, a company developed an AI [...]
Sandboxes done right: Why healthcare innovation stalls before it reaches patients
In 2017, a company developed an AI [...]
The 2026 Health Bill – what does it mean for NHS?
The 2026 Health Bill is one of [...]
CF announced as finalists for the 2026 MCA Awards
The MCA has announced finalists for its 2026 awards, and [...]
Deals, Data, and the NHS: Healthcare Investment in 2026
Last week CF’s Health Investing leadership team [...]
Reflections from IPPR’s new report launch – Bismarck versus Beveridge Revisited
Capital concerns I was in the room [...]
Agreement on pharmaceutical pricing between the United States and the United Kingdom
The UK and US governments have finalised [...]
ADHD Review: Interim findings lay bare the complexity of the ‘overdiagnosis’ debate
Amid growing debate around ADHD ‘overdiagnosis’, the UK [...]
